Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysis.
MGMT
glioblastoma
meta-analysis
systematic review
temozolomide
Journal
Neuro-oncology advances
ISSN: 2632-2498
Titre abrégé: Neurooncol Adv
Pays: England
ID NLM: 101755003
Informations de publication
Date de publication:
Historique:
entrez:
5
11
2020
pubmed:
6
11
2020
medline:
6
11
2020
Statut:
epublish
Résumé
The current standard of care for the management of patients with newly diagnosed glioblastoma (GBM) includes maximal safe resection followed by radiotherapy (RT) with concurrent and adjuvant temozolomide (TMZ). While it is well established that TMZ has better efficacy in patients with We conducted a systematic review and meta-analysis to provide separate estimates of median overall survival (OS) and progression-free survival (PFS) for patients with methylated and unmethylated GBM treated with RT with or without TMZ. We searched multiple databases from inception to January 13, 2020. The median OS for patients with unmethylated GBM treated with RT/TMZ pooled from 5 phase III studies ( This meta-analysis provides estimates of survival for patients with
Sections du résumé
BACKGROUND
BACKGROUND
The current standard of care for the management of patients with newly diagnosed glioblastoma (GBM) includes maximal safe resection followed by radiotherapy (RT) with concurrent and adjuvant temozolomide (TMZ). While it is well established that TMZ has better efficacy in patients with
METHODS
METHODS
We conducted a systematic review and meta-analysis to provide separate estimates of median overall survival (OS) and progression-free survival (PFS) for patients with methylated and unmethylated GBM treated with RT with or without TMZ. We searched multiple databases from inception to January 13, 2020.
RESULTS
RESULTS
The median OS for patients with unmethylated GBM treated with RT/TMZ pooled from 5 phase III studies (
CONCLUSIONS
CONCLUSIONS
This meta-analysis provides estimates of survival for patients with
Identifiants
pubmed: 33150334
doi: 10.1093/noajnl/vdaa082
pii: vdaa082
pmc: PMC7596890
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
vdaa082Commentaires et corrections
Type : ErratumIn
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.
Références
Nat Rev Neurol. 2014 Jul;10(7):372-85
pubmed: 24912512
J Mol Diagn. 2008 Jul;10(4):332-7
pubmed: 18556773
Lancet Oncol. 2013 Aug;14(9):823-33
pubmed: 23850491
Ann Intern Med. 2009 Aug 18;151(4):W65-94
pubmed: 19622512
Lancet Oncol. 2012 Jul;13(7):707-15
pubmed: 22578793
J Clin Oncol. 2009 Dec 1;27(34):5743-50
pubmed: 19805672
Front Neurol. 2018 Mar 21;9:127
pubmed: 29619003
N Engl J Med. 2014 Feb 20;370(8):699-708
pubmed: 24552317
Neuro Oncol. 2015 Nov;17(11):1425-7
pubmed: 26374690
Eur J Cancer. 2015 Mar;51(4):522-32
pubmed: 25616647
Clin Cancer Res. 2019 Mar 15;25(6):1809-1816
pubmed: 30514777
Oncotarget. 2017 Jan 24;8(4):7003-7013
pubmed: 27690294
Lancet Oncol. 2012 Sep;13(9):916-26
pubmed: 22877848
N Engl J Med. 2005 Mar 10;352(10):997-1003
pubmed: 15758010
J Transl Med. 2018 May 29;16(1):142
pubmed: 29843811
Acta Neuropathol Commun. 2019 Jun 5;7(1):89
pubmed: 31167648
BMJ. 2019 Aug 28;366:l4898
pubmed: 31462531
J Neurooncol. 2011 Jul;103(3):595-602
pubmed: 21052775
Curr Neurol Neurosci Rep. 2015 Jan;15(1):507
pubmed: 25394859
N Engl J Med. 2017 Mar 16;376(11):1027-1037
pubmed: 28296618
Lancet. 2019 Feb 16;393(10172):678-688
pubmed: 30782343
JAMA. 2017 Dec 19;318(23):2306-2316
pubmed: 29260225
Lancet Oncol. 2014 Sep;15(10):1100-8
pubmed: 25163906
Lancet Oncol. 2017 Oct;18(10):1373-1385
pubmed: 28844499
Clin Cancer Res. 2020 Jun 1;26(11):2664-2672
pubmed: 31953312
J Clin Oncol. 2013 Nov 10;31(32):4085-91
pubmed: 24101040
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Neuro Oncol. 2010 Feb;12(2):116-21
pubmed: 20150378
N Engl J Med. 2014 Feb 20;370(8):709-22
pubmed: 24552318